Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises

Exelixis reported solid earnings and outlined a franchise-focused growth strategy centered on expanding CABOMETYX in renal cell carcinoma and neuroendocrine tumors. Management is also advancing zanzalintinib through multiple late-stage development programs, supporting a positive outlook for the oncology pipeline. The update could provide a modest catalyst for EXEL shares, though no financial figures or guidance details were provided.